---
title: "VK2735 in Chronic weight management: Clinical presentation - signs and symptoms"
description: "Formulary evidence on VK2735 in Chronic weight management: Clinical presentation - signs and symptoms. Topics: Respiratory symptoms: sleep-disordered breathing, breathlessness, and wheezing; Musculoskeletal symptoms: joint pain and restricted mobility; Cardiovascular symptoms: heart failure, atrial fibrillation, and raised blood pressure; Metabolic signs: hyperglycemia and dyslipidemia; 6 further topics. 10 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description/clinical-presentation-signs-and-symptoms"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: Clinical presentation - signs and symptoms

<a id="heading-2.2.1.6"></a>

## 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

### Respiratory symptoms: sleep-disordered breathing, breathlessness, and wheezing

> “Upper airway obstruction caused directly by obesity results in development of sleep disordered breathing, which exists on a spectrum, from snoring with increased upper airways resistance, to obstructive sleep apnoea and obesity hypoventilation syndrome.”
> “The physical effects of increased intra-abdominal and central adiposity on diaphragmatic compliance and lung function can also contribute to breathlessness, especially during periods of increased oxygen requirements such as physical activity, or during respiratory infection (including COVID-19).”
> “Wheezing can exist as an isolated symptom or exacerbate pre-existing respiratory diseases such as asthma and COPD.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.6-2"></a>

### Musculoskeletal symptoms: joint pain and restricted mobility

> “Osteoarthritis, particularly affecting large, weight-bearing joints such as the hips and knees, develops as a direct effect of increased body size on these joints.”
> “Osteoarthritis compounded by excess body weight is associated with discomfort and pain, restricting mobility, which in turn contributes to further weight gain.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.6-3"></a>

### Cardiovascular symptoms: heart failure, atrial fibrillation, and raised blood pressure

> “Chronic fatigue, lower limb edema due to impaired diastolic dysfunction- Heart Failure with Preserved Ejection Fraction - HFpEF”
> “Evidence in the past several years shows relatively rapid and sizeable improvements in major heart failure symptoms with drug-induced and lifestyle-induced weight loss among people with heart failure with preserved ejection fraction.”
> “Obesity is also causally associated with atrial fibrillation, with preliminary evidence of reduced incident atrial fibrillation from large weight loss (eg, >10% of total body mass).”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.6-4"></a>

### Metabolic signs: hyperglycemia and dyslipidemia

> “In line with such interactions, many people with obesity present with raised triglycerides, surrogate evidence of excess liver fat, and often with reduced HDL cholesterol and elevated blood glucose and HbA1c concentrations.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.6-5"></a>

### Reproductive and urinary symptoms: menstrual disturbance, infertility, hypogonadism, and incontinence

> “The clinical symptoms of these disorders are menstruation disturbances (due to impaired ovulation), hirsutism, acne, and impaired fertility.”
> “In men, obesity is a cause of hypogonadotropic hypogonadism resulting in spermatogenesis disturbances and erectile dysfunction.”
> “Urinary incontinence is common in women with obesity and develops due to high intra-abdominal pressure combined with pelvic floor dysfunction.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.6-6"></a>

### Neurological symptoms: headache, visual loss, and peripheral neuropathy

> “Idiopathic intracranial hypertension, which typically presents with progressive and severe headaches, visual loss due to papilloedema, or both, is a less common but serious consequence of obesity.”
> “Obesity can also contribute to the development of peripheral neuropathy, independent of glycaemic status.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.6-7"></a>

### Lymphatic and skin signs: lymphoedema and intertrigo

> “Lymphoedema of the lower limbs is strongly associated with severe obesity, particularly in women, which develops due to mechanical compression of lymphatic vessels and reduced drainage, with feelings of pain, tightness, or both, resulting in decreased range of motion.”
> “Skin-on-skin rubbing and excessive moisture damage skin, causing inflammation and rash (eg, intertrigo), which predispose skin to fungal and bacterial infections.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.6-8"></a>

### Functional symptoms: limitation of activities of daily living

> “Obesity often generates disability that restricts routine activities of daily living, including aspects of its management, such as physical activity, meal preparation, and access to care.”
> “Physical restrictions can limit mobility, balance, and range of motion, impairing self-care activities including personal hygiene, bathing, toileting, dressing, and skin or foot care.”
> “Risks of falls causing injury are higher, related to poor mobility and postural stability, especially in people with class 2 or 3 obesity.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.6-9"></a>

### Psychological symptoms: depression and disordered eating

> “Obesity at baseline increased the risk of onset of depression at follow-up (unadjusted OR, 1.55; 95% confidence interval [CI], 1.22-1.98; P < .001).”
> “However, depression increased the odds for developing obesity (OR, 1.58; 95% CI, 1.33-1.87; P < .001).”

Source: [Luppino et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20194822/)

> “Eating disorders are common among people living with obesity, especially binge eating disorder and night eating syndrome.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.6-10"></a>

### Social symptoms: weight stigma and discrimination

> “People with obesity commonly face a pervasive, resilient form of social stigma. They are often subject to discrimination in the workplace as well as in educational and healthcare settings.”
> “Research indicates that weight stigma can cause physical and psychological harm, and that affected individuals are less likely to receive adequate care.”

Source: [Rubino et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7154011/)

> “Weight discrimination is reported by 19–42% of adults with higher BMI, particularly women.”
> “Health-services professionals are a common source of weight bias, which can lead to avoidance or delay in people seeking advice from health-care professionals.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
